Alector (ALEC) Other Non-Current Liabilities (2018 - 2026)
Alector (ALEC) reported Other Non-Current Liabilities of $1.8 million for Q1 2026, up 26.97% year-over-year from $1.4 million in Q1 2025, and up 1.9% quarter-over-quarter from $1.7 million in Q4 2025.
Alector (ALEC) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Other Non-Current Liabilities data on file, last reported at $1.8 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $1.8 million, up 26.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 26.97% YoY), and the FY2025 annual result was $1.7 million, up 40.76% from the prior year.
- Other Non-Current Liabilities rose to $1.8 million in Q1 2026 per ALEC's latest filing, from $1.7 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.8 million in Q1 2026 and troughed at $158000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities jumped 468.35% in 2023, then fell 10.12% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $759000.0 in 2022, then soared by 80.9% to $1.4 million in 2023, then slipped by 10.12% to $1.2 million in 2024, then jumped by 40.76% to $1.7 million in 2025, then rose by 1.9% to $1.8 million in 2026.
- Business Quant data shows ALEC's Other Non-Current Liabilities at $1.8 million in Q1 2026, $1.7 million in Q4 2025, and $1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.77 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 898,000.00 |
| Jun 30, 2023 | 898,000.00 |
| Mar 31, 2023 | 898,000.00 |
| Dec 31, 2022 | 759,000.00 |
| Sep 30, 2022 | 233,000.00 |
| Jun 30, 2022 | 233,000.00 |
| Mar 31, 2022 | 158,000.00 |
| Dec 31, 2021 | 158,000.00 |
| Sep 30, 2021 | 158,000.00 |
| Jun 30, 2021 | 158,000.00 |